Publications
Detailed Information
Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Jong In | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Lee, Sung-Hee | - |
dc.contributor.author | Byun, Hee Jin | - |
dc.contributor.author | Kim, Won | - |
dc.contributor.author | Lee, Hyo-Suk | - |
dc.contributor.author | Myung, Sun-Jung | - |
dc.contributor.author | Lee, Soo-Mi | - |
dc.date.accessioned | 2012-05-29T06:41:06Z | - |
dc.date.available | 2012-05-29T06:41:06Z | - |
dc.date.issued | 2010-01 | - |
dc.identifier.citation | AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY; Vol.298 1; G126-G132 | ko_KR |
dc.identifier.issn | 0193-1857 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76557 | - |
dc.description.abstract | Yang JI, Yoon J-H, Bang Y-J, Lee S-H, Lee S-M, Byun HJ, Myung S-J, Kim W, Lee H-S. Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 298: G126-G132, 2010. First published November 12, 2009; doi:10.1152/ajpgi.00299.2009.-Statinhas antifibrotic efficacy in human fibrosing diseases, such as pulmonary and renal fibrosis, and is therefore implicated in hepatic fibrosis. However, statin can also activate protein kinase C (PKC), which augments hepatic fibrogenesis and is thereby likely to reduce the antifibrotic efficacy of statin. This study was designed to explore the hypothesis that simultaneous treatment with statin and PKC inhibitor may synergistically enhance antifibrotic efficacy in hepatic fibrosis. Hepatic fibrosis models were established in BALB/c mice by intraperitoneal injection of carbon tetrachloride or thioacetamide for 6 wk. Pravastatin and enzastaurin (PKC inhibitor) were administered by gavage for 5 wk. Cellular apoptosis was explored using 4`,6-diamidino-2-phenylindole or terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick end-labeling (TUNEL) staining and immunoblot analysis. Hepatic fibrosis and hepatic stellate cell (HSC) activation were assessed by morphometric analysis of histological findings and immunohistochemistry for alpha-smooth muscle actin. In vitro, the addition of PKC inhibitor significantly increased statin-induced LX-2 cell apoptosis by enhancing the activation of mitochondrial apoptotic signals. TUNEL-positive HSCs were significantly increased in mice treated with statin + PKC inhibitor compared with those in control or single compound-treated mice. The percentage of area occupied by activated HSCs and the extent of collagen deposition were significantly decreased in mice treated with statin + PKC inhibitor compared with those in control or statin-treated mice. In conclusion, simultaneous treatment with statin and PKC inhibitor synergistically enhanced the antifibrotic efficacy in both in vitro and in vivo models of hepatic fibrosis and may therefore have therapeutic implication for reducing hepatic fibrosis. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | AMER PHYSIOLOGICAL SOC | ko_KR |
dc.subject | liver fibrosis | ko_KR |
dc.subject | pravastatin | ko_KR |
dc.subject | apoptosis | ko_KR |
dc.subject | enzastaurin | ko_KR |
dc.title | Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 양종인 | - |
dc.contributor.AlternativeAuthor | 윤정환 | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.contributor.AlternativeAuthor | 이성희 | - |
dc.contributor.AlternativeAuthor | 이수미 | - |
dc.contributor.AlternativeAuthor | 변희진 | - |
dc.contributor.AlternativeAuthor | 명선정 | - |
dc.contributor.AlternativeAuthor | 김원 | - |
dc.contributor.AlternativeAuthor | 이효석 | - |
dc.identifier.doi | 10.1152/ajpgi.0299.2009 | - |
dc.citation.journaltitle | AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | - |
dc.description.citedreference | Kim W, 2009, CANCER CHEMOTH PHARM, V64, P497, DOI 10.1007/s00280-008-0897-1 | - |
dc.description.citedreference | Myung SJ, 2009, J PHARMACOL EXP THER, V330, P276, DOI 10.1124/jpet.109.151860 | - |
dc.description.citedreference | Aprigliano I, 2008, LIVER INT, V28, P546, DOI 10.1111/j.1478-3231.2008.01682.x | - |
dc.description.citedreference | Bao N, 2007, CIRC J, V71, P1622 | - |
dc.description.citedreference | El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061 | - |
dc.description.citedreference | Robertson MJ, 2007, J CLIN ONCOL, V25, P1741, DOI 10.1200/JCO.2006.09.3146 | - |
dc.description.citedreference | De Minicis S, 2007, GASTROENTEROLOGY, V132, P1937, DOI 10.1053/j.gastro.2007.02.033 | - |
dc.description.citedreference | Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542 | - |
dc.description.citedreference | Chilakapati J, 2007, TOXICOLOGY, V230, P105, DOI 10.1016/j.tox.2006.11.050 | - |
dc.description.citedreference | Saka M, 2006, CLIN EXP PHARMACOL P, V33, P1164, DOI 10.1111/j.1440-1681.2006.04508.x | - |
dc.description.citedreference | Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003 | - |
dc.description.citedreference | Carducci MA, 2006, J CLIN ONCOL, V24, P4092, DOI 10.1200/JCO.2005.05.3447 | - |
dc.description.citedreference | Louneva N, 2006, ARTHRITIS RHEUM, V54, P1298, DOI 10.1002/art.21723 | - |
dc.description.citedreference | LAW M, 2006, AM J CARDIOL, V97, P52 | - |
dc.description.citedreference | MININO AM, 2006, NATL VITAL STAT REP, V54, P1 | - |
dc.description.citedreference | Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071 | - |
dc.description.citedreference | Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282 | - |
dc.description.citedreference | Xu L, 2005, GUT, V54, P142, DOI 10.1136/gut.2004.042127 | - |
dc.description.citedreference | Pinzani M, 2005, J HEPATOL, V42, pS22, DOI 10.1016/j.jhep.2004.12.008 | - |
dc.description.citedreference | CHANG ML, 2005, WORLD J GASTROENTERO, V11, P4167 | - |
dc.description.citedreference | Tanaka K, 2004, CLIN EXP PHARMACOL P, V31, P360 | - |
dc.description.citedreference | Li C, 2004, AM J PHYSIOL-RENAL, V286, pF46, DOI 10.1152/ajprenal.00428.2002 | - |
dc.description.citedreference | Kamada Y, 2003, GASTROENTEROLOGY, V125, P1796, DOI 10.1053/S0016-5085(03)01509-9 | - |
dc.description.citedreference | Yoshiji H, 2003, HEPATOL RES, V27, P51, DOI 10.1016/S1386-6346(03)00160-8 | - |
dc.description.citedreference | Rombouts K, 2003, J HEPATOL, V38, P564, DOI 10.1016/S0168-8278(03)00051-5 | - |
dc.description.citedreference | Jaster R, 2003, BIOCHEM PHARMACOL, V65, P1295, DOI 10.1016/S0006-2952(03)00075-3 | - |
dc.description.citedreference | Ramm GA, 2003, DIGEST DIS SCI, V48, P790 | - |
dc.description.citedreference | Friedman SL, 2003, J HEPATOL, V38, pS38, DOI 10.1016/S0168-8278(02)00429-4 | - |
dc.description.citedreference | Honda H, 2002, HEPATOLOGY, V36, P12, DOI 10.1053/jhep.2002.33684 | - |
dc.description.citedreference | Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130 | - |
dc.description.citedreference | Benyon RC, 2000, GUT, V46, P443 | - |
dc.description.citedreference | Di Sario A, 1999, GASTROENTEROLOGY, V116, P1155 | - |
dc.description.citedreference | Jacobsen W, 1999, DRUG METAB DISPOS, V27, P173 | - |
dc.description.citedreference | Tan A, 1999, AM J RESP CRIT CARE, V159, P220 | - |
dc.description.citedreference | Iredale JP, 1998, J CLIN INVEST, V102, P538 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.